Chronic hepatitis B is a global public health problem. The latest information shows that there are nearly 100 million people infected with hepatitis B virus in China, and the vast majority of this population is positive for hepatitis B surface antigen, while a very small number may be negative for hepatitis B surface antigen or hepatitis B “two-and-a-half”, but the hepatitis B virus can be detected in blood or liver tissue. There are about 30 million chronic hepatitis B patients in this population, and every year a certain percentage of them develop into hepatitis cirrhosis and primary liver cancer. 2007, nearly 1200 cases of primary liver cancer were reported in our city, and 1700 cases died. Therefore, it is especially important to adhere to scientific and standardized treatment follow-up for chronic hepatitis B. First, regular physical examination and monitoring is the key. As chronic hepatitis B does not have very obvious conscious symptoms, it is often easy to be ignored, while if there are obvious symptoms such as fatigue and weakness, yellow eyes, yellow urine, loss of appetite, nausea and vomiting, it is often an attack of chronic hepatitis B. Regular medical checkups at specialist hospitals, liver function checkups every 3 – 6 months, quantitative hepatitis B two-to-one, DNA, ultrasound every six months, and at least one annual checkup of alpha-fetoprotein and liver fibrosis index for people over 30 years old. This is all good behavior to treat their health scientifically. Second, clarify the stage of the disease, targeted. Chronic hepatitis B has different disease stages, which can be divided into viral carriers, chronic hepatitis, hepatitis cirrhosis, etc., of which viral carriers are the lightest, but this group of people are easy to ignore, and easy to be “fooled”. The most important thing is that this group of people is easily overlooked and easily “fooled”. At present, no effective treatment has been researched for virus carriers, and any excessive medical treatment is futile. Chronic hepatitis B virus carriers will enter the chronic hepatitis stage one after another after a long process of 10 to 20 years. The early or late emergence depends on a variety of factors (time of infection, transmission route, genetic background, viral genes, immune status, etc.), and in the state of viral carriage (also known as the immune tolerance stage), we need to adhere to regular follow-up monitoring, once liver function abnormalities recur and factors such as alcohol, drugs and fatty liver are excluded, it indicates that the chronic hepatitis B stage has been entered (a small number of patients need to be determined by liver tissue biopsy), and the chronic hepatitis stage is entered. (A small number of patients need to be determined by liver tissue biopsy), and entering the chronic hepatitis stage requires us to take active standardized treatment. Third, standardized treatment and reasonable expectations are guaranteed. The effective treatment drugs recognized at home and abroad for chronic hepatitis B are long-acting interferon, common interferon and nucleoside (acid) drugs, such as entecavir, lamivudine, adefovir and telbivudine, etc. The decision of which drug to use for treatment depends on the patient’s condition, preference for treatment methods (injectable vs. oral administration), economy, etc. It also depends on the communication between the specialist and the patient, so that the patient It is not advisable to determine the treatment plan blindly or arbitrarily. Once standardized treatment is administered, patients should have clear and reasonable expectations: normalization of liver function, hepatitis B DNA below the lower limit of detection, conversion of hepatitis B e antigen and seroconversion (hepatitis B e antibody conversion). When each of these results occurs and can be maintained, the desired goal of a negative hepatitis B surface antigen is likely to occur. One third of patients achieve the desired result with long-term treatment with one drug, and a large proportion of patients need to adjust or combine another antiviral drug, which requires patients to be monitored by regular follow-up visits during treatment and to establish a long-term stable contact with a specialist. Fourth, eliminate misconceptions and increase confidence. 1, the rush to quick success, quick fix. Chronic hepatitis B patients are eager to quickly cure the disease, but most of the current effective treatments can only inhibit the replication of the virus and slow down the progress of the disease. By fighting the disease relentlessly over a long period of time, it is possible to overcome hepatitis B. Now the course of interferon (ordinary, long-acting) at least one year, oral antiviral drugs for at least two years. 2, worry about the virus drug-resistant mutation. Many chronic hepatitis B patients are always worried about virus resistance mutation after medication, but also worried about the future of their own disease without special drugs, so always at the doorstep of standard treatment wandering. In fact, this kind of worry often delays the treatment of the disease, thus also misses the time of treatment again and again. The correct attitude should be to actively and boldly pursue antiviral therapy as long as it meets the treatment indications. Because the goal of our treatment is to inhibit and reduce the hepatitis B virus in the body, thereby stabilizing liver function and delaying disease progression. 3, the arbitrariness of drug selection. A variety of drugs are available for chronic hepatitis B. The ideal solution is to use drugs with strong antiviral ability and low incidence of drug resistance. Some patients do not use medication under the supervision of a specialist for a long time, change the treatment medication at will, or do not follow up after stopping the medication as required, which is extremely detrimental to the control of chronic hepatitis B and needs to be taken seriously.